Recent developments and future perspectives of personalized oncology

Onkologie

Volumn 35, Issue SUPPL. 1, 2012, Pages 4-7

  Grüllich, Carsten ^a   Von Kalle, Christof ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Individualized therapy; Molecular analysis; Molecular carcinogenesis; Molecular targeted therapy

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 [4 (2 DIMETHYLAMINOETHOXY)PHENYL] 4 (1 HYDROXYIMINO 5 INDANYL) 5 (4 PYRIDINYL) 1H IMIDAZOLE; 4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; CABOZANTINIB; CRIZOTINIB; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; GSK 461364; IMATINIB; KX 2391; LAPATINIB; LESTAURTINIB; MIDOSTAURIN; MK 5108; NINTEDANIB; PROTEIN; PROTEIN EML4; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB;

BREAST CANCER; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; DIAGNOSTIC ACCURACY; DRUG INDICATION; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; LUNG CANCER; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; ONCOLOGY; PERSONALIZED MEDICINE; REVIEW;

FORECASTING; HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 84856465513     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/0003348254     Document Type: Review

References (11)

1. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916. (Pubitemid 32064784)
2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037. (Pubitemid 32267972)
3. Joensuu H, Dimitrijevic S: Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. Ann Med 2001;33:451-455. (Pubitemid 32959916)
4. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al.: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056. (Pubitemid 32267975)
5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-782.
6. Price DK, Figg WD: Mutations in the EGFR: the importance of genotyping. Cancer Biol Ther 2004;3:434-435. (Pubitemid 41350855)
7. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al.: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-2096.
8. Butrynski JE, D'Adamo DR, Hornick JL, Dal CP, Antonescu CR, Jhanwar SC, et al.: Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010;363:1727-1733.
9. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al.: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-819.
10. Kim ES, Hong WK: The BATTLE Trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44.
11. Biankin AV, Kench JG, Colvin EK, Segara D, Scarlett CJ, Nguyen NQ, et al.: Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology 2009;137:558-568, 568.e1-11.